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ABSTRACT 
Objective: The objective of this study was to prepare nanosuspension of a practical water insoluble antiulcer drug which is lafutidine to enhance 
the solubility, dissolution rate with studying the effect of different formulation variables to obtain the best formula with appropriate physical 
properties and higher dissolution rate.  
Methods: Nanosuspension of lafutidine was prepared using solvent anti-solvent precipitation method using Polyvinylpyrrolidone K-90(PVP K-90) 
as the stabilizer. Ten formulations were prepared to show the effect of different variables in which two formulations showed the effect of stabilizer 
type, three formulations showed the effect of stabilizer concentration, two formulations showed the effect of combination of polymer with 
surfactant such as tween 80, three formulations show the effect of stirring speed and three formulations prepare to show the effect of addition of co-
surfactant such as tween 20. All these formulations are evaluated for their particle size and entrapment efficiency and in vitro release. The selected 
one was evaluated for zeta potential, scanning electron microscope, atomic force microscopy, Fourier transforms infrared spectroscopy, differential 
scanning calorimetry, saturation solubility and stability study. 
Results: The formulations (F3-F10) were in the nano size. The optimum concentration of the stabilizer was in the formulation when the drug: 
polymer: surfactant ratio 1:4:4 and the optimum stirring speed was 1500 rpm. Dramatic effect on the particle size reduction was found by the 
addition of co-surfactant (tween 20) in formulation F7 that has a particle size 15.89±1.8 nm. The selected formula F7 showed an enhanced 
dissolution profile (10 min) compared to the pure drug at all-time intervals. 
Conclusion: The results show that the formulation that contains drug: PVP-K90: tween 80: tween 20 in ratio 1:4:2:2 is the best one and can be 
utilized to formulate lafutidine nanosuspension. 
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Approximately 75% of new chemical entities are poorly soluble in 
aqueous medium and many even in the organic medium [1]. 
Solubility is quantitatively defined as the concentration of solute in a 
saturated solution at a certain temperature, while qualitatively may 
be defined as the spontaneous interaction of two or more substances 
for formation of a homogeneous molecular dispersion [2]. So many 
problems arising from poor new drug solubility in drug research and 
development. Also, low solubility limits the drug dissolution rate, 
resulting in low bioavailability of the oral drug [3]. As a result, 
extensive attempts have been carried out to solve the problems of 
low aqueous solubility and increase the dissolution rate of 
hydrophobic drugs. Some of the conventional approaches are 
particle size reduction method which subclasses into a) 
micronization: There are general methods of particle size reduction, 
such as milling and spray drying, rely upon mechanical stress to 
disaggregate the active compound. In addition to that micronization 
approach successfully enhanced the bioavailability of poorly water-
soluble drugs such as griseofulvin and felodipine [4, 5]. b) 
nanonization: is the production of drug nanocrystals, and it is a 
common approach to overcome poor drug solubility in water. 
Nanonization produces drug particles below 1 micron either by the 
bottom-up methods such as precipitation and self-assembly or top-
down technologies such as milling and high-pressure homogenization. 
Nanonization has an advantage of increased saturation solubility of 
the drug together with the increase in dissolution rate [6]. 
Nanosuspensions technology has been conceived as a candidate for 
efficient delivery of hydrophobic drugs and applied to poorly soluble 
drugs since this technology results in the formulation that is having 
high dissolution velocity and increased saturation solubility [7]. 
Other advantages of nanosuspension are that it can be easy 
fabrication into a tablet or a capsule or dried nanosuspension form 
which can easily be re-dispersible [8]. 
Nanosuspension is a submicron colloidal dispersion of drug 
particles. So a pharmaceutical nanosuspension is defined as a very 
finely colloid, biphasic, dispersed, solid drug particles in the aqueous 
vehicle, with size below 1μm, without any matrix material, stabilized 
by surfactants and polymers (stabilizer)[9]. 
Lafutidine is a yellowish white crystalline powder[10], with a 
melting point of (98.87-101.57 °C), It is freely soluble in glacial 
acetic acid, DMF, soluble in methanol, sparingly soluble in 
dehydrated ethanol, very slightly soluble in ether, practically 
insoluble in water with logp = 3.8 [11]. Lafutidine has pka =3.9 and 
according to Biopharmaceutical Classification System (BCS), It 
belongs to class II of drug category [12].  
Lafutidine is a new H2-receptor antagonist, after absorption in the small 
intestine; it reaches gastric cells by the systemic circulation, then directly 
and quickly binds to gastric cell histamine H2 receptors, resulting in 
prompt inhibition of gastric acid secretion. It is selectively absorbed from 
the upper part of small intestine (absorption window) [13]. The drug is 
predominantly metabolized in the liver mainly by microsomal enzyme 
CYP3A4, and CYP2D6 and its major metabolites are sulfonyl lafutidine 
and hydroxylated lafutidine [14]. Fasting plasma concentration of the 
unchanged drug observed as Tmax: 0.8±0.1 h; Cmax: 174±20 ng/ml. It 
has a biological half-life of 3.0 h [15]. 
The aim of the study was to the formulation of lafutidine as 
nanosuspension to improve its solubility and enhance in vitro 
dissolution rate.  
 
 
Fig. 1: Chemical structure of lafutidine [12] 
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MATERIALS AND METHODS 
Materials 
Lafutidine powder was purchased from Hangzhou hyper chemicals 
limited, Zhejiang, China. Tween 80 and tween 20, was purchased 
from Scharlau S. L Spain. (PVP K-90) was provided by Hangzhou 
hyper chemicals limited, Zhejiang, China. Dialysis membrane70 
provided by HIMEDIA (Mumbai, India). All other chemicals and 
solvents were of analytical reagent grade, and deionized water also 
was used in this study. 
Methods 
Preparation of lafutidine nanosuspension by precipitation 
method 
Nanosuspension precipitation method is used to prepare oral 
nanosuspension of lafutidine using a different concentration of 
polymer and surfactant. In brief, 10 mg of lafutidine was dissolved in 
an organic solvent (1 ml methanol). Deionized water containing the 
stabilizer (PVP K-90or tween 80) alone at the drug: stabilizer ratio 1:8 
or in the combination of PVP K-90 with tween 80 at the different 
concentration or in combination with co-surfactant (tween 20), which 
acts as the antisolvent system. This was followed by the addition of the 
organic solution into the antisolvent solution by the help of a syringe 
pump, under mechanical agitation of different speeds using homo 
disperser for 60 min at 25±1°C to allow organic solvent to evaporate 
and get the desired nanosuspension [16]. The batches were prepared 
according to the formulation design (table 1). 
Evaluation of the prepared nanosuspension 
Particle size and size distribution 
Particle size determination was done by using Angstrom Advanced Inc. 
ABT-9000 USA particle size analyzer which is a dynamic light scattering 
works by measuring the intensity of light scattered by the molecules in 
the sample as a function of time, at scattering angle 90° and a constant 
temperature of 25 °C. From the analysis, the average particle size which 
is also called volume moment mean, (mean diameter in nm) reflects the 
size of those particles which constitute the bulk of the sample volume 
and it was measured for all the prepared formulas. The polydispersity 
index (PDI) which is a measure of the width of the size distribution of 
each formula of LAF nanosuspension also determined, it is a measure of 
the distribution of particle size of nanoparticles obtained from a particle 
analyzer, PDI is an index of spread or variation or width within the 
particle size distribution. Also, the analyzer determines the specific 
surface area of each sample [17]. 
 
Table 1: Composition of lafutidine nanosuspension formulation 
Substance F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
LAF (mg) 10 10 10 10 10 10 10 10 10 10 
PVP-K90 (mg) 80 - 50 40 30 50 40 30 50 50 
Tween 80 (mg) - 74.8 28 37.4 46.7 14 18.7 23.4 28 28 
Tween 20 (ml) - - - - - 13.6 18.2 22.7 - - 
Methanol (ml) 1 1 1  1 1 1 1 1  1 1 
Water (ml) 30  30 30  30  30  30  30  30  30 30 
Stirring speed (rpm) 1500 1500 1500 1500 1500 1500 1500 1500 500 3000 
F: formula, LAF: Lafutidine, PVP K-90: Polyvinylpyrrolidine k-90, rpm: round per min  
 
Determination of entrapment efficiency (EE) of nanosuspension  
10 ml of nanosuspension was centrifuged at 6000 rpm for 20 min. 
The supernatant solution was filtered and separated. 1 ml of this 
filtrate was diluted with water and the absorbance at maximum λ 
max was measured by UV spectrophotometer using water as blank 
[18]. The amount of free drug in the formulations was measured and 
the entrapment efficiency is then calculated from Eq.1 
E. E% =
(	   	– )∗
	   	
 ……. (1) 
The results were analyzed in triplicate and standard deviations are 
reported. 
In vitro dissolution profile of nanosuspension  
In vitro drug release for nanosuspension was done by using Himedia 
dialysis membrane (MWCO 12 KD). Volume containing 10 mg of 
lafutidine of (F3-F10) nanosuspension was placed in the pretreated 
dialysis bag and drug release was done using USP dissolution 
apparatus II containing 900 ml of dissolution medium at 37 ± 0.5 °C. 
The speed of the paddle was 100 rpm. The formulation of lafutidine 
nanosuspension was subjected to the drug release studies in media 
of 0.1N HCl (pH 1.2) in comparison with a pure drug. Samples (5 ml) 
were withdrawn at intervals of 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 
100, 110 and 120 min respectively), and replenished with the 
equivalent volume of fresh dissolution medium to maintain the 
constant volume. Then, samples were filtered and assayed 
spectrophotometrically on UV spectrophotometer at 286 nm 
wavelength. The experiment repeated in triplicate for each 
formulation [19]. 
Zeta potential 
Zeta potential of the selected formulation of lafutidine 
nanosuspension was measured by using (NanoSeries, Nano-ZS, 
Malvern Instruments, UK). A zeta potential value of±30mV is 
required as a minimum for physically stable nanosuspension 
stabilized by electrostatic repulsion only. While zeta potential of 
about±20 mV is sufficient to of high-intensity the nanosuspension 
system stabilized by a combination of steric and electrostatic 
stabilization [20]. 
The freeze-drying of selected formula 
Freeze drying or lyophilization was carried out using christ (ALPHA 
1-4 LD plus) to retrieve nanoparticles in a dried-powder state from 
the nanosuspensions, to complete characterization of 
nanosuspension and show the effect of freeze drying on 
nanoparticles size and solubility so water-removal was conducted 
through freeze-drying. The selected formula was used containing 
2% w/w mannitol as the cryoprotectant, to prevent agglomeration 
was frozen in a refrigerator at-70 °C for 24 h. Then the sample was 
lyophilized using vacuum freeze dryer at a controlled temperature 
of (-44) °C and the pump operating at the pressure of 2.5 × 10 
pascals over the range of 48–72 hr. The obtained powder was used 
for further studies [21]. 
Fourier transforms infrared spectroscopy (FTIR) 
The fourier transforms infrared spectroscopy spectra of pure 
lafutidine and lyophilized powder of the selected formula were 
obtained using FTIR spectrophotometer (FTIR-8300 Shimadzu, 
Japan) by potassium bromide (KBr) pellet method. This study was 
achieved to identify any sign of interaction between the drug and 
stabilizer used. The spectrum obtained was in between the wave 
number of 4000-400 cm-1[22]. 
Scanning electron microscopy (SEM) 
Scanning electron microscope used for observing the morphology of 
samples, SEM of pure lafutidine, and lyophilized powder was 
confirmed by direct deposition of powder on double-sided carbon 
tape and coated with gold; the analysis of the particle size was 
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performed using the UTHSCSA Image Tool software. Five to six high 
resolution and high magnification pictures of SEM representative of 
the sample were used to find the particle size. The program was 
used to measure the average size of the particles seen in each of the 
SEM picture [23]. 
X-ray powder diffraction  
Powder x-ray diffraction can be used to confirm the crystalline 
nature of materials. So, this information is used to verify whether 
the substances are crystalline or amorphous. The diffractograms 
of lafutidine and lyophilized powders of the selected formulation 
were obtained for analysis. The study was confirmed by using 
Shimadzu XRD-6000 powder X-ray diffractometer at continuous 
scan range of 10-80 degree. The operating voltage was 40 (kV) and 
current 30mA [24]. 
Statistical analysis  
The experimental results are given as mean triplicate samples 
standard deviation (SD) and were analyzed according to one-way 
analysis of variance (ANOVA) using Sigma Plot 11 software at which 
the results would be significant if p<0.05, and the results would be 
nonsignificant if p>0.05.  
RESULTS AND DISCUSSION 
Particle size analysis and polydispersity index measurement  
The effect of different parameters on the particle size and polydispersity 
index was studied using ten different formulations. The mean particle 
size (effective diameter) for formulations varied in the wide range from 
6.358±0.0 nm to 1188±1.7 nm. The particle size and PDI for different 
formulations of different parameters is showing in table 2. 
 
Table 2: The particle size, and PDI of different formulations 
Formula no. P. S.±SD* PDI±SD* 
F1 1188±1.7 0.324±0.0 
F2 805.2±1.7 0.489±0.0 
F3 22.9±0.0 0.048±0.0 
F4 73.0±11.9 0.893±0.0 
F5 63.55±0.0 0.278±0.0 
F6 19.08±0.0 0.405±0.0 
F7 15.89±1.8 1.0±0.0 
F8 6.358±0.0 0.196±0.0 
F9 36.14±0.0 0.481±0.0 
F10 59.5±0.0 0.703±0.0 
*SD standard deviation, n=3, P. S.: Particle size, PDI: Polydispersity index 
 
Effect of stabilizer type on the particle size and polydispersity index 
Two formulations were used to show this effect F1, F2. The best 
stabilizer was in F2 (tween 80) which has particle size 805.2±1.7 
nm. Also, this formulation show PDI in the value of 0.489 and this 
low value will indicate good stability of the nanosuspension. The 
effect of stabilizer type shown in the fig. 2. The choice of suitable 
stabilizers are the most important factors to control the size and 
stability of the nanosuspension during nanoprecipitation methods 
[25]. Although; the mechanism of action of PVP K-90 which was used 
as hydrophilic polymers to stabilize nanosuspensions physically by 
steric stabilization; but they gave larger particle in ratios 1:8 drug: 
stabilizer in F1(p<0.05) than particle size of F2 which contain tween 
80, this may be attributed to the insufficient affinity of stabilizers to 
drug molecule. However, if there is no affinity between the particle 
surface and the polymer, the attractive forces between two particles 
become dominant due to depletion of polymer from the gap of two 
particles (depletion force) [26]. 
Effect of combination of surfactant with polymer on particle 
size and polydispersity index 
F3 was used to show the effect of combination of tween 80 (used as 
surfactant) with PVP K-90 (used as polymer) as compared with F1 
and F2 that used these stabilizers alone (fig. 3), When PVP K-90 used 
as a primary stabilizer in F1, could not significantly decrease the 
particle size (p>0.05) to nanosized particles; therefore, it could not 
be used as the single stabilizer for the nanosuspension. The use of 
tween 80 combined with another stabilizer (PVP K-90) as in fig. 3 
may disperse drug particle into the aqueous solution and decrease 
the particle size [27]. The combination of surfactant (tween80) with 
PVP K-90 provide the electrostatic-steric mechanism, surfactant 
found to influence the particle size which helps in preventing growth 
and stabilize the particles primarily by adsorption at the solid-liquid 
interface and reduction of the interfacial tension leading to an 
increased rate of nucleation [28]. 
The most significant effect (p<0.05) of surfactant combination with 
one polymer was shown in formulas that contain tween 80 or PVP-
K90 as primary stabilizer, as in F1and F2 respectively at ratio 1:8 
(drug: primary stabilizer), the particle size was 1188 nm and 805.2 
nm respectively, while in F3 in which tween 80 combined with PVP 
K-90 at drug: polymer: surfactant ratio 1:5:3 the particle sizes were 
22.9 nm. That means the combination has the good surface affinity 
and could form a substantial mechanical and thermodynamic barrier 
at the interface of drug molecule [29]. Polydispersity index values of 
F3 was 0.048, indicate that these formulas are monodisperse 
standard, there are significant differences (p<0.05) from PDI values 
of F1 and F2 that were 0.324-0.489 indicate that these formulas are 
midispersed standard.  
Effect of stabilizer concentration on the particle size and 
polydispersity index 
Three formulations were used to show this effect F3, F4, and F5. In fig. 
4 the particle size of F5 containing PVP K-90 and tween 80 at drug: 
polymer: surfactant ratio 1:5:3 was increased significantly (p<0.05) 
from 22.9 nm to 73 nm in F4 when the surfactant concentration raised 
to drug: polymer: surfactant ratio 1:4:4 and then the particle size 
decrease significantly (p<0.05) to 5.248 nm in F5. 
It was observed that with an increase in surfactant concentration in 
the nanosuspension from the particle size of the nanosuspension 
decreases. This was due to the decrease in relative viscosity, which 
led to decrease in particle size. It means that hydrodynamic 
diameter of particle decreased with increase in the concentration of 
the surfactant. The concentration of surfactant affected on particle 
size because too little concentration of stabilizer induces 
agglomeration or aggregation and too much concentration promotes 
Ostwald ripening [30].  
Effect of addition co-surfactant on particle size and poly-
dispersity index 
The addition of co-surfactant is also preferred for long-term 
stabilization and decrease particle size significantly(p<0.05) as in 
fig. 5, F6-F8 studied the effect of the combination of surfactants 
(tween 80 and tween 20) on the particle size that range 6.358-19.08 
nm which smaller than F3, F4 and F5 that contain one surfactant 
(tween 80), these findings are in accordance with another study 
whose particle sizes was lower and better stability when stabilized 
the formulation with surfactant mixtures compared with 
Dawood et al. 
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formulations with only one surfactant [31]. PDI of F8 and F6 were 
0.196, and 0.405 respectively this show that these formulas were 
dispersed while F7 was polydisperse because it had PDI equal to 1.0. 
Effect of stirring speed on the particle size and polydispersity 
index of prepared nanosuspension 
Three different speeds 500, 1500 and 3000 rpm were used to 
prepare three formulations F9, F3, and F10 to show this effect as in 
fig. 6. In this study the optimums speed at the drug: polymer: 
surfactant ratio 1:5:3 was found to be 1500 rpm that produce mean 
particle size 22.9±0.0 nm. PDI of these formulations was in the range 
of 0.048-0.703. The result suggested that lafutidine nanoparticles 
were nonsignificantly affected (p>0.05) by stirring speed, the 
decreased particle size with increased stirring speed is due to an 
intensification of micromixing (i. e, mixing of molecular level) 
between multi-phases. High micromixing efficiency increased mass 
transfer and the rate of diffusion between the multi-phases which 
induced high homogeneous supersaturation in short time, thus rapid 
nucleation to produced smaller drug particle. In addition to that, a 
high stirring speed prevents the particle growth by preventing their 
aggregation. Hence the formation of smaller and more uniform drug 
particles with high stirring speed [32]. 
However, further increase in the stirring speed led to increasing in 
the particle size (p>0.05)of nanosuspension during precipitation 
method that resulted in non-uniform formulations with visible 
settling due to the aggregation of particles, this could be due to 
mechanical agitation and non-uniform mixing producing local 
regions of supersaturation during anti-solvent precipitation [33]. 
 
 
Fig. 2: Effect of stabilizer type on the particle size of 
nanosuspension (Results as an as mean, n=3) 
 
 
Fig. 3: Effect of a combination of the surfactant with polymer on 
the particle size of nanosuspension (n=3) 
 
Fig. 4: Effect of stabilizer concentration on the particle size of 
nanosuspension (Results are expressed as mean, n=3) 
 
 
Fig. 5: Effect of addition of co-surfactant on particle size (n=3) 
 
 
Fig. 6: Effect of addition of stirring speed on particle size 
(Results are expressed as mean, n=3) 
 
Drug entrapment efficiency  
The Percentage drug entrapment efficiency of the formulations was 
calculated and the results were 95.604%, 98.54%, 96.34%, 98.43%, 
98.74%, 98.54, 94.56% and 97.5 for F3, F4, F5, F6 F7, F8, F9 and F10 
respectively. The drug entrapment efficiency of F7 was high when 
compared to other formulations. Drug entrapment efficiency was 
significantly affected by the addition of non-ionic surfactants 
(combination of tween80 with tween 20) with ratio of drug: 
polymer: surfactant (1:4:4) with higher EE% (98.74%) in F7 (fig. 8) 
which could be due to decreased partitioning of LAF into the outer 
aqueous phase and better dispersion obtained by adding a 
hydrophilic surfactants [34]. 
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Fig. 7: Particle size distribution of the selected formula (F7) 
 
 
Fig. 8: Drug entrapment efficiency of the prepared formulation of lafutidine nanosuspension (Results are expressed as mean, n=3) 
 
In vitro dissolution study  
The dissolution profile of the formulas that in nanosize (F3-F10) 
were studied in 0.1N HCl of pH 1.2 to determine the best formula 
that gives the best release in first 10 min. The release of F3-F10 is 
presented 0.1N HCl of pH 1.2 in fig. (9). From the study, the results 
showed that the formula F7 that contain PVP K-90, tween 80 and 
tween 20 stabilizers gave the best release in 10 min in comparison 
with other formulas and the formula shows a maximum cumulative 
percentage drug release of 100 % within 10 min. 
From the above result depending on the particle size and PDI will be 
the formula no. F7 which has the mean particle size (15.89±0.0 nm) 
and E. E% (98.74). F7 was considered as the selected formula 
because it had the highest dissolution rate, highest entrapment 
efficiency percentage and low particle size when compared with 
another formula. This formula is selected for zeta potential 
measurement study, lyophilization, and further study. 
Zeta potential 
The zeta potential for the selected formulation of lafutidine 
nanosuspension was-23 mV as shown in fig. 11. The charge was 
negative due to adsorbed tween 80, tween 20 and PVP K-90 on the 
drug particles; however, this result of zeta potential proposes that 
the nanosuspension was adequately stabilized. It reflects the 
electrical potential of particles and is influenced by the composition 
of the particles and the medium in which it is dispersed. Zeta 
potential gives certain information about the surface charge 
properties and furthers the long-term physical stability of the 
nanosuspension. The obtained value for selected formulation 
indicates stable nanosuspension [35]. 
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Fig. 9: In vitro drug release profile of lafutidine formulation nanosuspension in 0.1N HCl at 37±0.5 °C (n=3) 
 
 
Fig. 10: In vitro drug release profile of selected formula (F7) compared with pure powder lafutidine in 0.1N HCl at 37±0.5 °C (Results are 
expressed as mean, n=3) 
 
Fig. 11: Zeta potential of the selected formula (F7) 
 
Saturation solubility of freeze-drying nanosuspension 
The batch F7 (lafutidine: PVP K-90: tween 80: tween 20 1:4:2:2) was 
selected for freeze drying. In this study, 2% of mannitol was added 
as the cryoprotectant for avoiding nanocrystals aggregation/ 
agglomeration. Mannitol containing samples showed good re-
dispersibility upon manual shaking. The results of the solubility 
study indicated that pure lafutidine had a very low solubility in 
water(0.078 mg/ml) which considered as practically insoluble in 
water, while the saturation solubility of lafutidine nanoparticle in 
lyophilized powder was (125.5 mg/ml) greater than that of pure 
drug which considered as freely soluble in water. This may be due to 
the reduction in particle size of lafutidine to nano size which results 
in exposure of more surface area and enhanced hydrophilicity; these 
Dawood et al. 
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were responsible for the significantly enhanced (p<0.05) saturation 
solubility [36]. 
Fourier transforms infrared spectroscopy  
The Fourier transforms infrared spectra of pure lafutidine shown in 
fig. 12 (A) and that of the lyophilized powder of the selected formula 
(F7) intensity in fig. 12 (B). FTIR spectra of lafutidine 
nanosuspension show no change in shifting the position of the 
lafutidine nanosuspension functional groupspeak and this will 
indicate there was no an interaction between the drug and the 
stabilizer PVP K-90 and other excipients (tween80 and tween 20) 






Fig. 12: Fourier transforms infrared spectroscopy of A) lafutidine and B) lyophilized powder 
 
Scanning electron microscope 
Scanning electron microscope of pure lafutidine, PVP K-90 and 
lyophilized powder are presented in fig. (13, 14, and 15) at 1K, 5K, 
10K, 50K and 500x (this only for PVP K-90) magnification. The 
scanning electron microscope study for pure lafutidine powder 
showed large particles with crystalline needle shape with the 
smooth surface, while scanning electron microscope of PVP K-90 
elucidated the irregular shape with the rough surface of PVP K-90 
particle because it was the amorphous polymer [38]. 
Scanning electron microscope of lyophilized powder at 1K, 5K, 10K 
and 50K of magnification revealed that the decreased the particle 
size with some of the crystalline needle structure of drug this 
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Fig. 14: Scanning electron microscope of PVP K-90 (A, B, C, D, and E) at 1K, 5K, 10K, 50K and 500X magnification respectively 
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Fig. 15: Scanning electron microscope of lyophilized powder (A, B, C, and D) at 1K, 5K, 10K and 50K magnification respectively 
 
Fig. 16: Powder X-ray diffraction analysis of pure lafutidine 
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Powder x-ray diffraction analysis (PXRD) 
To confirm the physical state of lafutidine, PVP K-90 and lyophilized 
powder x-ray diffraction were performed. The Powder X-ray 
diffraction analysis patterns of lafutidine as a pure drug exhibited 
intense crystalline peaks at the 2θ angle as in fig. 16, the strongest 
three peaks were 17.2 °, 19.8 °, and 20.3 °. The diffraction patterns of 
PVP K-90 demonstrated in fig. 17. PVPK-90 indicated the halo pattern 
was revealing amorphous nature of polymer as in it’s diffractogram 
and characterized by low intense peak. However, the strongest peaks 
of PVP K-90 at the 2θ angle were 11.29 °, 43.9 and 64.29 °. The 
diffused peaks at higher angles confirm the semi-crystalline nature of 
the polymer [39]. However, the characteristic crystalline peak at the 
2θ angle of 20.3 ° became lower intensity peak, and strongest peaks of 
17.2 °, 19.8 ° disappeared in the pattern of lyophilized powder as in fig. 
18 producing another peak at the 2θ angle of 5.69 ° and 20.6 °. This 
study suggested that there was no significant difference in 
characteristic peaks position of lafutidine in the lyophilized powder. 
Accordingly, all types of energy input during preparation and the 
attendance of stabilizer did not change the crystallinity of lyophilized 
nanosuspension powder. A just difference detected between the 
coarse powder, and lafutidine nanosuspension was in the peak 
intensity and presented of high-intensity peaks, probably attributed to 
particle size reduction, stabilizer at the surface [40]. 
 
Fig. 17: Powder x-ray diffraction analysis of the PVP K-90 
 
Fig. 18: Powder X-ray diffraction analysis of the selected formula F7 
 
CONCLUSION 
It may be concluded from the results of this study that 
nanosuspensions of particle water-insoluble drug lafutidine can be 
prepared using solvent anti-solvent precipitation method and using 
PVP K90, tween 80, and tween 20 as stabilizers.  
The process parameters, such as stabilizer type, the combination of 
the surfactant with the polymer, stabilizer concentration, stirring 
speed and combination of other stabilizer were investigated and 
optimized to produce the smallest drug nanoparticles. The 
dissolution rate of the nanosuspension significantly enhances as 
compare with the pure drug.  
Dawood et al. 




We are very thankful to College of Pharmacy, University of Basrah, 
Iraq; for providing necessary facilities utilized in carrying out parts 
of the work. 
AUTHORS CONTRIBUTIONS 
All the author have contributed equally 
CONFLICT OF INTERESTS 
Declared none 
REFERENCES 
1. Marano S, Barker SA, Raimi-Abraham BT, Missaghi S, Rajabi-
Siahboomi A, Craig DQ. Development of micro-fibrous solid 
dispersions of poorly water-soluble drugs in sucrose using 
temperature-controlled centrifugal spinning. Eur J Pharm 
Biopharm 2016;103:84-94.  
2. Martin’s physical pharmacy and pharmaceutical sciences. 4th 
Edition; 2006. p. 220.  
3. Loh ZH, Samanta AK, Heng PW. Overview of milling techniques 
for improving the solubility of poorly water-soluble drugs. 
Asian J Pharm Sci 2015;10:255-74.  
4. K Ramesh B, Chandra S, Podile K. Formulation and evaluation 
of poorly soluble etravirine by spray drying method. Int J 
Pharm Pharm Sci 2015;7:98-103.  
5. Bhairav BA, Bachhav JK, Saudagar RB. Review on solubility 
enhancement techniques. Asian J Pharm Res 2016;6:175-80. 
6. Khadka P, Ro J, Kim H, Kim I, Kim JT, Kim H, et al. 
Pharmaceutical particle technologies: an approach to improve 
drug solubility, dissolution, and bioavailability. Asian J Pharm 
Sci 2014;9:304-16.  
7. Kayaert P, Van den Mooter G. Is the amorphous fraction of a 
dried nanosuspension caused by milling or by drying? a case 
study with naproxen and cinnarizine. Eur J Pharm Biopharm 
2012;81:650-6. 
8. Amin MA, Osman SK, ALY UF. Preparation and characterization 
of ketoprofen nanosuspension for solubility and dissolution 
velocity enhancement. Int J Pharm Bio Sci 2013;4:768-80.  
9. Sutradhar KB, Khatun S, Luna IP. Increasing possibilities of 
nanosuspension. J Nanotech 2013. 
http://dx.doi.org/10.1155/2013/346581 
10. Agrawal G, Atrey R, Mishra P. A stability-indicating high 
performance liquid chromatographic analytical method for the 
determination of lafutidine in the tablet. Der Pharm Lett 
2015;7:38-43. 
11. Parveen A, Reddy RS. Formulation and in vitro evaluation of 
gastroretentive bilayer floating tablets of clarithromycin and 
lafutidine. Int J Pharm Tech 2014;6:6651-70. 
12. Lolitas D. Design and evaluation of lafutidine floating tablets 
for controlled release by using semi-synthetic and natural 
polymer. J Drug Discovery Ther 2014;24:2. 
13. Sravanthi N, Bandari D. Effect of super disintegrants on 
solubility and dissolution rate of lafutidine. Int J Adv Tech Eng 
Sci 2015;3:275-89. 
14. Patel MD, Patel GD, Patel NC. Formulation and optimization of 
the raft-forming chewable tablet containing lafutidine. Int J 
Pharm Sci Drug Res 2015;7:229-34. 
15. Patel DM, Patel DG, Patel CN. Formulation and optimization of a 
raft-forming chewable tablet containing lafutidine. Int J Pharm 
Sci Drug Res 2015;7:229-34.  
16. Pandya VM, Patel JK, Patel DJ. Formulation, optimization and 
characterization of simvastatin nanosuspension prepared by 
nanoprecipitation technique. Pharm Lett 2011;3:129-40. 
17. Jassim ZE, Hussein AA. Formulation and evaluation of 
clopidogrel tablet incorporating drug nanoparticles. Int J 
Pharm Pharm Sci 2014;6:838-51.  
18. Shid RL, Dhole SN, Kulkarni N, Shid SL. Formulation and 
evaluation of nanosuspension formulation for drug delivery of 
simvastatin. Int J Pharm Sci Nanotech 2014;7:2650-65. 
19. Sahu BP, Das MK. Nanosuspension for enhancement of oral 
bioavailability of felodipine. Appl Nanosci 2014;4:189-97. 
20. Papdiwal A, Pande V, Aher S. Investigation of an effect of 
different stabilizers on a formulation of zaltoprofen 
nanosuspension. Int J Pharm Sci Rev Res 2014;27:244-9. 
21. Deore S, Nerkar P, Mahajan H, Ige P. Formulation and 
evaluation of nanosuspension formulations polymers. Int J 
Pharm Sci Nanotechnol 2014;8:5-14. 
22. Gadad AP, Naik SS, Dandagi PM, Bokmal UB. Formulation and 
evaluation of gastroretentive floating microspheres of 
lafutidine. Indian J Pharm Educ Res 2016;50Suppl:76-81. 
23. Kakran M, Sahoo GN, Li L. Fabrication of nanoparticles of 
silymarin, hesperetin and glibenclamide by evaporative 
precipitation of nanosuspension for fast dissolution. Pharm 
Anal Acta 2015;6:2. 
24. Jassem NA, Rajab NA. Formulation and in vitro evaluation of 
azilsartan medoxomil nanosuspension. Int J Pharm Pharm Sci 
2017;9:110-9. 
25. Wu L, Zhang J, Watanabe W. Physical and chemical stability of 
drug nanoparticles. Adv Drug Delivery Rev 2011;63:456-69. 
26. Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for 
preparing drug nanocrystals: formulations and factors affecting 
particle size. Int J Pharm 2013;453:1-15.  
27. Amin MA, Osman SK, AlyUF. Preparation and characterization 
of ketoprofen nanosuspension for solubility and dissolution 
velocity enhancement. Int J Pharm Bio Sci 2013;4:768-80. 
28. Krishna K, Hiral K, Navin S, Mahesh D. The impact of critical 
variables on properties of nanosuspension: a review. Int J Drug 
Dev Res 2015;7:150-61. 
29. Rachmawati H, Shaal LA, Müller RH, Keck CM. Development of 
curcumin nanocrystal: physical aspects. J Pharm Sci 
2013;102:204-14. 
30. Zu Y, Sun W, Zhao X, Wang W, Li Y, Ge Y, et al. Preparation and 
characterization of amorphous amphotericin B nanoparticles 
for oral administration through liquid anti-solvent 
precipitation. Eur J Pharm Sci 2014;53:109-17. 
31. Senthil Kumar P, Arivuchelvan A, Jagadeeswaran A, Subramanian 
N, Senthil Kumar C, Mekala P. Formulation, optimization and 
evaluation of enrofloxacin solid lipid nanoparticles for sustained 
oral delivery. Asian J Pharm Clin Res 2015;8:231-6. 
32. Yeole BD, Patil RP, Lone KD, Tekade AR. Preparation of 
nanoparticles of poorly water-soluble dronedarone by 
antisolvent addition technique using the natural polymer as a 
stabilizer. J Pharm Res Clin Prac 2016;6:8-16. 
33. Gera S, Talluri S, Rangaraj N, Sampathi S. Formulation and 
evaluation of naringenin nanosuspensions for enhancement. 
AAPS PharmSciTech 2017;18:3151-62. 
34. Maaz A, Abdelwahed W, Tekko IA, Trefi S. Influence of 
nanoprecipitation method parameters on nanoparticles loaded 
with gatifloxacin for ocular drug delivery. Int J Acad Sci Res 
2014;3:1-2. 
35. Jünemann D, Dressman J. Analytical methods for dissolution 
testing of nanosized drugs. J Pharm Pharmacol 2012;64:931-43. 
36. Ahuja BK, Jena SK, Paidi SK, Bagri S, Suresh S. Formulation, 
optimization and in vitro–in vivo evaluation of febuxostat 
nanosuspension. Int J Pharm 2015;478:540-52. 
37. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of 
oral bioavailability of poorly water-soluble drugs. 
Am J Pharmacol Sci 2015;10:13-23. 
38. Fu X, Kong W, Zhang Y, Jiang L, Wang J, Lei J. Novel solid-solid 
phase change materials with biodegradable trihydroxy 
surfactants for thermal energy storage. RSC Adv 2015;5:68881-9. 
39. Mishra B, Sahoo J, Dixit PK. Fabrication of cinnarizine 
nanosuspensions by ultrasonication technique: a systematic 
study of formulation parameters on particle size and in vitro 
dissolution. Biopharm J 2017;1:12-21. 
40. Vora C, Patadia R, Mittal K, Mashru R. Preparation and 
characterization of dipyridamole solid dispersions for 
stabilization of supersaturation: effect of precipitation inhibitors 
type and molecular weight. Pharm Dev Tech 2016;21:847-55. 
 
